Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Sagent Pharmaceuticals, Inc.
Type
Subsidiary
Industry Biotechnology
Founded 2007
Key people

Allan Oberman (CEO)

Jonathon Singer (CFO)
Revenue $318 million
Net income
$23 million
Website sagentpharma.com

Allan Oberman (CEO)

Sagent Pharmaceuticals is a biopharmaceutical company founded in 2007. The company received series A funding of $53 million, as well as $40 million in two rounds of series B funding. As part of the funding, Zhejiang Hisun Pharmaceutical Co. Ltd made an investment of $10 million in Sagent. In total, the company has raised $153 million in equity capital. In 2011 the company filed for IPO - offering 5,750,000 shares of common stock at a price to the public of $16 per share

The company was acquired by Nichi-Iko Pharmaceutical Co., Ltd in 2016.

In 2010, the company entered a partnership with Actavis to market and supply a number of injectable products.

In 2014, the company announced its intention to acquire Omega Laboratories Limited for $85.3 million

In 2015, the company sold Sagent (China) Pharmaceuticals to Nanjing King-Friend Biochemical Pharmaceutical Co.

In 2016, the company made its most notable acquisition to date, when it acquired five Abbreviated New Drug Applications from Teva Pharmaceuticals for $40 million. As part of Teva's acquisition on Actavis Generics, a number of drug portfolios are being sold off. Later in the same year, the company was acquired by Nichi-Iko Pharmaceutical Co., Ltd for $736 million (representing $21.75 per share and a 40% share premium).

Official website

Investment goal date:
Dividends reinvested
Sagent Pharmaceuticals, Inc. SGNT report Q2 2016
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q3 2016
2016-11-05
--
--
Q2 2016
2016-08-09
0.0000
-0.0200
Q1 2016
2016-05-03
-0.1500
-0.1500
Q4 2015
2016-02-16
0.8300
-0.5500
Q3 2015
2015-11-03
-0.0500
-0.0500
Q2 2015
2015-08-04
-0.0100
-0.0100
Q1 2015
2015-05-05
-0.0600
-0.0600
Q4 2014
2015-02-19
0.1700
0.9000
Q3 2014
2014-11-04
0.0600
0.0600
Q2 2014
2014-07-30
0.0900
0.0900
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
CATAPULT CAPITAL MANAGEMENT LLC
60000
LMCG INVESTMENTS, LLC
19664
RUSSELL FRANK CO/
362327
VTL Associates, LLC
8654
Major Shareholders
Name Relationship
Total Shares
Holding stocks
YORDON JEFFREY
1.9300% (616076)
SGNT /
KUNG FRANK
0.1200% (36909)
SGNT /
MORGAN STANLEY INVESTMENT MANAGEMENT INC
9.8700% (3147052)
SGNT /
HUSSEY JAMES M
0.0300% (11058)
SGNT /
FLANAGAN ROBERT J
0.0400% (12200)
SGNT /
Behrens Mary Taylor
0.0200% (7097)
HMA / SGNT /
Pauli Ronald
0.0100% (3680)
HZNP / SGNT /
Harmon J Frank
0.0300% (8915)
SGNT /
Singer Jonathon M
0.1200% (38728)
LDR / RTIX / SGNT /
Vivo Ventures V, LLC
0.1100% (34961)
CAPN / MEIP / SGNT /
Vivo Ventures VI, LLC
0.0800% (25320)
SGNT /
Krizman Anthony
0.0200% (7097)
SGNT /
Patterson Albert
0.1500% (48690)
SGNT /
Drake Lorin
0.1200% (39172)
SGNT /
Logerfo Michael
0.1700% (53292)
SGNT /
China Renaissance Capital Investment II GP
8.7100% (2779003)
SGNT /
Greve Jeffrey W.
0.0200% (4962)
SGNT /
FEKETE MICHAEL
0.0200% (5651)
SGNT / SPNE /
SHEA THOMAS JOSEPH
0.0300% (10442)
SGNT /
OBERMAN ALLAN
0.3200% (101986)
SGNT /
% ()